# CNS Sector

Canonical URL: https://biopharmsignal.com/sector/cns

CNS refers to central nervous system diseases such as depression, schizophrenia, epilepsy, Alzheimer's disease, Parkinson's disease, and other neurological or psychiatric conditions. Companies on this page are grouped by their exposure to brain and nervous system therapeutics.

Companies currently grouped under CNS: 92

## Recent Sector News

- 2026-10-07 11:00 EST — AXSM — [Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2](https://biopharmsignal.com/news/AXSM/axsome-therapeutics-to-report-third-quarter-2026-financial-results-on-november-2-54e70163) — Source: Axsome
- 2026-10-06 11:05 EST — PMN — [ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer](https://biopharmsignal.com/news/PMN/promis-neurosciences-appoints-seasoned-alzheimer-s-and-neuroscience-executive-iv-70ff0cb8) — Source: ProMIS Neurosciences
- 2026-10-06 10:00 EST — MNOV — [MediciNova to Participate in the Maxim Growth Summit](https://biopharmsignal.com/news/MNOV/medicinova-to-participate-in-the-maxim-growth-summit-b4c1d735) — Source: MediciNova
- 2026-10-05 13:17 EST — NMTC — [NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order](https://biopharmsignal.com/news/NMTC/neuroone-reports-preliminary-fiscal-q4-product-revenue-growth-of-38-4-secures-re-c72b40ba) — Source: NeuroOne Medical Technologies
- 2026-10-05 11:05 EST — ATHE — [Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders](https://biopharmsignal.com/news/ATHE/alterity-therapeutics-presents-new-analyses-of-ath434-phase-2-data-in-multiple-s-94663fbf) — Source: Alterity Therapeutics
- 2026-10-02 21:00 EST — XERS — [Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XERS/xeris-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-723b15a4) — Source: Xeris Pharmaceuticals
- 2026-10-02 20:01 EST — XENE — [Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-f8979511) — Source: Xenon
- 2026-10-02 20:01 EST — PRAX — [Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing--de4d1df8) — Source: Praxis Precision Medicines
- 2026-10-02 20:01 EST — IKT — [Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-56-ae2dfdcf) — Source: Inhibikase Therapeutics
- 2026-10-02 15:20 EST — BIIB — [Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus](https://biopharmsignal.com/news/BIIB/biogen-s-litifilimab-demonstrates-rapid-and-durable-efficacy-in-new-52-week-phas-bb06832e) — Source: Biogen
- 2026-10-02 12:00 EST — TSHA — [Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635--18c0402b) — Source: Taysha Gene Therapies
- 2026-10-02 12:00 EST — TEVA — [Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome](https://biopharmsignal.com/news/TEVA/teva-presents-new-efficacy-and-safety-data-with-ecopipam-an-investigational-trea-b199e324) — Source: Teva Pharmaceutical Industries
- 2026-10-02 12:00 EST — TEVA — [Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients](https://biopharmsignal.com/news/TEVA/journal-of-child-neurology-publishes-review-highlighting-dopamine-s-role-in-tour-74c002b6) — Source: Teva Pharmaceutical Industries
- 2026-10-02 05:00 EST — ADXN — [Addex Therapeutics Announces Executive Management Changes](https://biopharmsignal.com/news/ADXN/addex-therapeutics-announces-executive-management-changes-3fdf34b1) — Source: Addex Therapeutics
- 2026-10-01 13:28 EST — GANX — [Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration](https://biopharmsignal.com/news/GANX/gain-therapeutics-presents-positive-phase-1b-open-label-extension-data-for-rexac-65cdd7bc) — Source: Gain Therapeutics
- 2026-10-01 12:05 EST — HRMY — [Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days](https://biopharmsignal.com/news/HRMY/harmony-biosciences-announces-poster-presentation-at-the-17th-european-narcoleps-8ca2eb7d) — Source: Harmony Biosciences
- 2026-10-01 12:00 EST — TSHA — [Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-multiple-encore-presentations-supporting-tsha-10-88119405) — Source: Taysha Gene Therapies
- 2026-09-30 20:32 EST — TEVA — [TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness](https://biopharmsignal.com/news/TEVA/tapi-technology-api-services-names-serge-rogasik-ceo-to-lead-next-chapter-of-gro-0e515be3) — Source: Teva Pharmaceutical Industries
- 2026-09-30 12:30 EST — NBIX — [Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-research-advancing-understanding-of-prader-wil-3d23c3bd) — Source: Neurocrine Biosciences
- 2026-09-30 11:00 EST — ANL — [Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations](https://biopharmsignal.com/news/ANL/adlai-nortye-appoints-christopher-liu-pharmd-as-head-of-investor-relations-and-p-bb7eff83) — Source: Adlai Nortye Ltd.

## Companies

- [ABBV](https://biopharmsignal.com/company/ABBV) — AbbVie Inc
- [ABVC](https://biopharmsignal.com/company/ABVC) — ABVC BioPharma, Inc.
- [ACIU](https://biopharmsignal.com/company/ACIU) — AC Immune
- [ACAD](https://biopharmsignal.com/company/ACAD) — ACADIA Pharmaceuticals Inc.
- [ABOS](https://biopharmsignal.com/company/ABOS) — Acumen Pharmaceuticals
- [ADXN](https://biopharmsignal.com/company/ADXN) — Addex Therapeutics
- [ANL](https://biopharmsignal.com/company/ANL) — Adlai Nortye Ltd.
- [AEON](https://biopharmsignal.com/company/AEON) — AEON Biopharma
- [ALKS](https://biopharmsignal.com/company/ALKS) — Alkermes plc
- [ATHE](https://biopharmsignal.com/company/ATHE) — Alterity Therapeutics
- [ALZN](https://biopharmsignal.com/company/ALZN) — Alzamend Neuro
- [ALZH](https://biopharmsignal.com/company/ALZH) — Alzheon
- [AMPH](https://biopharmsignal.com/company/AMPH) — Amphastar Pharmaceuticals, Inc.
- [AMLX](https://biopharmsignal.com/company/AMLX) — Amylyx
- [ANNX](https://biopharmsignal.com/company/ANNX) — Annexon, Inc.
- [ANVS](https://biopharmsignal.com/company/ANVS) — Annovis Bio
- [ASRT](https://biopharmsignal.com/company/ASRT) — Assertio
- [ATAI](https://biopharmsignal.com/company/ATAI) — ATAI Life Sciences
- [ATHA](https://biopharmsignal.com/company/ATHA) — Athira Pharma
- [AXSM](https://biopharmsignal.com/company/AXSM) — Axsome
- [BIIB](https://biopharmsignal.com/company/BIIB) — Biogen
- [BHVN](https://biopharmsignal.com/company/BHVN) — Biohaven
- [BNOX](https://biopharmsignal.com/company/BNOX) — Bionomics
- [BTAI](https://biopharmsignal.com/company/BTAI) — BioXcel
- [BCLI](https://biopharmsignal.com/company/BCLI) — Brainstorm Cell Therapeutics Inc.
- [SAVA](https://biopharmsignal.com/company/SAVA) — Cassava Sciences
- [CPRX](https://biopharmsignal.com/company/CPRX) — Catalyst Pharmaceutical
- [CERE](https://biopharmsignal.com/company/CERE) — Cerevel
- [CRVO](https://biopharmsignal.com/company/CRVO) — CervoMed
- [CLNN](https://biopharmsignal.com/company/CLNN) — Clene Inc.
- [CGTX](https://biopharmsignal.com/company/CGTX) — Cognition Therapeutics
- [CMPS](https://biopharmsignal.com/company/CMPS) — COMPASS Pathways Plc
- [CYCN](https://biopharmsignal.com/company/CYCN) — Cyclerion
- [DNLI](https://biopharmsignal.com/company/DNLI) — Denali Therapeutics
- [ECOR](https://biopharmsignal.com/company/ECOR) — electroCore
- [ENVB](https://biopharmsignal.com/company/ENVB) — Enveric Biosciences
- [GANX](https://biopharmsignal.com/company/GANX) — Gain Therapeutics
- [GHRS](https://biopharmsignal.com/company/GHRS) — GH Research
- [HRMY](https://biopharmsignal.com/company/HRMY) — Harmony Biosciences
- [HSDT](https://biopharmsignal.com/company/HSDT) — Helius Medical Technologies
- [IGC](https://biopharmsignal.com/company/IGC) — IGC Pharma, Inc.
- [IKT](https://biopharmsignal.com/company/IKT) — Inhibikase Therapeutics
- [ITCI](https://biopharmsignal.com/company/ITCI) — Intra-Cellular Therapies
- [JAZZ](https://biopharmsignal.com/company/JAZZ) — Jazz Pharmaceuticals
- [JNJ](https://biopharmsignal.com/company/JNJ) — Johnson & Johnson
- [LNTH](https://biopharmsignal.com/company/LNTH) — Lantheus Holdings, Inc.
- [LBPH](https://biopharmsignal.com/company/LBPH) — Longboard Pharmaceuticals
- [MRNS](https://biopharmsignal.com/company/MRNS) — Marinus
- [MNOV](https://biopharmsignal.com/company/MNOV) — MediciNova
- [MNMD](https://biopharmsignal.com/company/MNMD) — MindMed
- [NERV](https://biopharmsignal.com/company/NERV) — Minerva Neuroscience
- [NGEN](https://biopharmsignal.com/company/NGEN) — NervGen Pharma
- [NMRA](https://biopharmsignal.com/company/NMRA) — Neumora Therapeutics
- [NRBO](https://biopharmsignal.com/company/NRBO) — NeuroBo
- [NBIX](https://biopharmsignal.com/company/NBIX) — Neurocrine Biosciences
- [NGNE](https://biopharmsignal.com/company/NGNE) — Neurogene
- [NURO](https://biopharmsignal.com/company/NURO) — Neurometrix
- [NMTC](https://biopharmsignal.com/company/NMTC) — NeuroOne Medical Technologies
- [NLSP](https://biopharmsignal.com/company/NLSP) — NLS Pharmaceutics Ltd.
- [NRXP](https://biopharmsignal.com/company/NRXP) — NRX Pharmaceuticals, Inc.
- [OGEN](https://biopharmsignal.com/company/OGEN) — Oragenics
- [ORPH](https://biopharmsignal.com/company/ORPH) — Orphazyme
- [OVID](https://biopharmsignal.com/company/OVID) — Ovid Therapeutics
- [KTTA](https://biopharmsignal.com/company/KTTA) — Pasithea Therapeutics
- [PASG](https://biopharmsignal.com/company/PASG) — Passage Bio
- [PRAX](https://biopharmsignal.com/company/PRAX) — Praxis Precision Medicines
- [PMN](https://biopharmsignal.com/company/PMN) — ProMIS Neurosciences
- [PTIX](https://biopharmsignal.com/company/PTIX) — Protagenic Therapeutics
- [PRTA](https://biopharmsignal.com/company/PRTA) — Prothena
- [RVPH](https://biopharmsignal.com/company/RVPH) — Reviva Pharmaceuticals
- [SAGE](https://biopharmsignal.com/company/SAGE) — Sage Therapeutics, Inc.
- [SANION](https://biopharmsignal.com/company/SANION) — Saniona
- [SNY](https://biopharmsignal.com/company/SNY) — Sanofi
- [SEEL](https://biopharmsignal.com/company/SEEL) — Seelos Therapeutics, Inc.
- [SLNO](https://biopharmsignal.com/company/SLNO) — Soleno Therapeutics
- [STOK](https://biopharmsignal.com/company/STOK) — Stoke Therapeutics
- [SUPN](https://biopharmsignal.com/company/SUPN) — Supernus
- [SNPX](https://biopharmsignal.com/company/SNPX) — Synaptogenix
- [TAK](https://biopharmsignal.com/company/TAK) — Takeda
- [TSHA](https://biopharmsignal.com/company/TSHA) — Taysha Gene Therapies
- [TEVA](https://biopharmsignal.com/company/TEVA) — Teva Pharmaceutical Industries
- [TNXP](https://biopharmsignal.com/company/TNXP) — Tonix Pharmaceuticals
- [TRVN](https://biopharmsignal.com/company/TRVN) — Trevena
- [TRVI](https://biopharmsignal.com/company/TRVI) — Trevi Therapeutics
- [QURE](https://biopharmsignal.com/company/QURE) — uniQure N.V.
- [VNDA](https://biopharmsignal.com/company/VNDA) — Vanda Pharmaceuticals
- [VTRS](https://biopharmsignal.com/company/VTRS) — Viatris Inc.
- [VIGL](https://biopharmsignal.com/company/VIGL) — Vigil Neuroscience
- [VTGN](https://biopharmsignal.com/company/VTGN) — Vistagen Therapeutics, Inc.
- [VYGR](https://biopharmsignal.com/company/VYGR) — Voyager Therapeutics
- [XENE](https://biopharmsignal.com/company/XENE) — Xenon
- [XERS](https://biopharmsignal.com/company/XERS) — Xeris Pharmaceuticals